Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 47 for your search:

Drug:  panitumumab
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase III Randomized Study of Irinotecan Hydrochloride With Versus Without Panitumumab or Cyclosporine in Patients With Fluorouracil-Resistant Advanced or Metastatic Colorectal Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CTRU-PICCOLO-MO-05-7289, EUDRACT-2005-003492-20, CTAAC-CTRU-PICCOLO-MO-05-7289, AMGEN-CTRU-PICCOLO-MO-05-7289, EU-20647, NCT00389870

Phase III Randomized Pilot Study of Neoadjuvant and Adjuvant Fluorouracil and Oxaliplatin With or Without Panitumumab in Patients With Resectable High-Risk Colon Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: BCTU-FOXTROT-001, BCTU-FOxTROT-001, ISCRTN 87163246, EUDRACT 2007-001987-55, EU-20830, MREC-07/S0703/57, UKCRN 3771, NCT00647530

Phase III Randomized Study of Standard Fractionation Radiotherapy and High-Dose Cisplatin Versus Accelerated Fractionation Radiotherapy and Panitumumab in Patients With Locally Advanced Stage III or IV Squamous Cell Carcinoma of the Head and Neck

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAN-NCIC-HN6, HN6, NCT00820248

REAL 3 Version 2.0: Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-Gastric Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CCR3024, NCT00824785

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer

Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20080763, ASPECCT, NCT01001377

Study to Evaluate AMG 706 with or without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20040153, NCT00094835

Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 82
Sponsor: Other
Protocol IDs: Pro00002207, SPS 151596, NCT00578071

Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 07326, NCT00667420

Panitumumab Combination Study With AMG 102 or AMG 479 in Wild-type KRAS mCRC

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060447, NCT00788957

10.

New Individualized Therapy Trial for Metastatic Colorectal Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BUS278T, NCT00867334

11.

ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20030250, NCT00089635

12.

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060141, NCT00418938

13.

PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20062088, NCT00446446

14.

Phase II Randomized Study of Erlotinib Hydrochloride and Gemcitabine Hydrochloride With Versus Without Panitumumab in Patients With Previously Untreated, Metastatic Adenocarcinoma of the Pancreas

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N064B, N064B, NCT00550836

15.

Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20062079, CONCERT2, NCT00547157

16.

Phase II Study of Panitumumab, Chemotherapy, and External-Beam Radiotherapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N064A, N064A, NCT00601627

17.

Phase II Study of Panitumumab and Irinotecan Hydrochloride as Third-Line Therapy in Patients With Previously Treated Metastatic Colorectal Cancer Without KRAS Mutation

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GERCOR-PIMABI-C07-1, GERCOR-PIMABI-C07-1, EUDRACT 2007-004806-28, EU-20836, AMGEN-GERCOR-PIMABI-C07-1, NCT00655499

18.

Phase II Study of Neoadjuvant Panitumumab, Docetaxel, Cisplatin, and Radiotherapy Followed By Surgery in Patients With Newly Diagnosed, Locally Advanced Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ACOSOG-Z4051, Z4051, NCT00757172

19.

Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: EudraCT 2008-002367-14, S-20080081, 2612-3769, NCT00779454

20.

Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EudraCT 2008-004923-48, S-20080104, LMS 2612-3844, NCT00792363

21.

Phase II Randomized Study of Neoadjuvant Capecitabine and Concurrent Radiotherapy With Versus Without Panitumumab in Patients With Advanced K-ras Unmutated Rectal Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SWS-SAKK-41/07, SAKK-41/07, EudraCT-2008-006012-38, EU-20894, NCT00814619

22.

Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: UPCI 06-120, NCT00798655

23.

PEAK: A Phase 2 Study of Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer Subjects With Wild-Type KRAS Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20070509, Non Applicable, NCT00819780

24.

Phase II Study of Irinotecan and Panitumumab

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 07-161, IND#102657, NCT00836277

25.

Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer

Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-287, 20070602, NCT00842257

Select All on Page

Help with Results

A Service of the National Cancer Institute